SCHEMBL3489425

SCHEMBL3489425

NC[C@H](O)c1ccc(Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.64
TSHR P16473 2/20 0.64
NFKB1 P19838 2/20 0.64
HTR3A P46098 1/20 0.64
HIF1A Q16665 1/20 0.64
APEX1 P27695 3/20 0.61
TDP1 Q9NUW8 3/20 0.61
KDM4E B2RXH2 2/20 0.61
ALOX15 P16050 1/20 0.61
AOC3 Q16853 1/20 0.57
GABBR2 O75899 6/20 0.53
GABBR1 Q9UBS5 6/20 0.53
LMNA P02545 4/20 0.52
BLM P54132 3/20 0.52
MAPT P10636 3/20 0.52
THRB P10828 3/20 0.52
HPGD P15428 2/20 0.52
RECQL P46063 2/20 0.52
MEN1 O00255 2/20 0.52
ADORA3 P0DMS8 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296405 1.00 TAAR1 (0.64) TAAR1TSHRNFKB1HTR3AHIF1A
SCHEMBL3488185 1.00 TAAR1 (0.64) TAAR1TSHRNFKB1HTR3AHIF1A
Hydrochloric Acid SCHEMBL1570355 0.98 APEX1 (0.65) TAAR1TSHRNFKB1HTR3AHIF1A
Hydrochloric Acid SCHEMBL3573909 0.98 APEX1 (0.65) TAAR1TSHRNFKB1HTR3AHIF1A
SCHEMBL4074768 0.87 TAAR1 (0.80) TAAR1TSHRNFKB1HTR3AHIF1A
SCHEMBL15809806 0.82 AOC3 (0.53) TAAR1TSHRNFKB1HTR3AHIF1A
SCHEMBL21199024 0.82 AOC3 (0.53) TAAR1TSHRNFKB1HTR3AHIF1A
SCHEMBL21199026 0.82 AOC3 (0.53) TAAR1TSHRNFKB1HTR3AHIF1A
SCHEMBL7490714 0.81 TAAR1 (0.64) TAAR1TSHRNFKB1HTR3AHIF1A
Hydrochloric Acid SCHEMBL21199119 0.80 AOC3 (0.52) TAAR1TSHRNFKB1HTR3AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2025-05-06 US disclosed
CN-112601749-B Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉因生物股份有限公司 2024-03-26 CN disclosed
US-20230107032-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-04-06 US disclosed
US-11414425-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2022-08-16 US disclosed
CN-112601749-A Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉因生物股份有限公司 2021-04-02 CN disclosed
US-20200048268-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-02-13 US disclosed
US-20100068771-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED BETA-AMINO ALCOLHOLS STARTING FROM GLYCINE AND AN ALDEHYDE IN THE PRESENCE OF A THREONINE ALDOLASE AND A DECARBOXYLASE DSM IP ASSETS B.V. (NL) 2010-03-18 US disclosed
CN-101473039-A Method for producing enantiomerically enriched beta-aminoalcohols starting from glycine and an aldehyde in the presence of a threonine aldolase and a decarboxylase DSM IP ASSETS BV (NL) 2009-07-01 CN disclosed
EP-2004836-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERI CALLY ENRICHED BETA-AMINO ALCOHOLS STARTING FROM GLYCINE AND AN ALDEHYDE IN THE PRESENCE OF A THREONINE ALDOLASE AND A DECARBOXYLASE DSMIP Assets B.V. (NL) 2008-12-24 EP disclosed
WO-2007118682-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERI CALLY ENRICHED BETA-AMINO ALCOHOLS STARTING FROM GLYCINE AND AN ALDEHYDE IN THE PRESENCE OF A THREONINE ALDOLASE AND A DECARBOXYLASE DSM IP ASSETS B.V. (NL) 2007-10-25 WO disclosed
EP-0924194-A2 Processes for producing optically active 2-amino-1-phenylethanol derivatives DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-06-23 EP disclosed
EP-0924193-A1 Processes for producing optically active 2-amino-1-phenylethanol derivatives DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-06-23 EP disclosed
US-5902900-A OPTICAL PURITY, USE AS ANTI-OBESITY AGENTS DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-05-11 US disclosed
US-5811293-A CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1998-09-22 US disclosed
US-5679557-A Process of asymmetrically reducing 1-phenyl-2-oxo-propane derivatives with microorganisms DAICEL CHEMICAL INDUSTRIES, LIMITED (JP) 1997-10-21 US disclosed
US-5629200-A MICROORGANISM DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1997-05-13 US disclosed
EP-0627397-B1 Optically active 1-phenyl-2-substituted propane derivatives and methods of producing the same DAICEL CHEM (JP) 1997-01-02 EP disclosed
US-5508461-A ANTIOBESITY AGENTS DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1996-04-16 US disclosed
EP-0654534-A2 Processes for producing optically active 2-amino-1-phenylethanol derivatives DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-24 EP disclosed
EP-0627397-A1 Optically active 1-phenyl-2-substituted propane derivatives and methods of producing the same DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1994-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107032-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GABRA5, GRM5, GABRA1 TAAR1 163/4885TSHR 423/4885NFKB1 1741/4885
US-11414425-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRA1 TAAR1 163/4885TSHR 423/4885NFKB1 1741/4885
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRA1 TAAR1 163/4885TSHR 423/4885NFKB1 1741/4885
US-20200048268-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GABRA5, GRM5, GABRA1 TAAR1 163/4885TSHR 423/4885NFKB1 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.